☆ 4.5 Article

SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data

EUROSURVEILLANCE (2021)

Related references

Note: Only part of the references are listed.

Article Multidisciplinary Sciences

Correlates of protection against SARS-CoV-2 in rhesus macaques

Katherine McMahan et al.

Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.

NATURE (2021)

Add to Collection

Article Medicine, General & Internal

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

R. Libster et al.

Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Constantinos Kurt Wibmer et al.

Summary: The SARS-CoV-2 virus in the B.1.351 variant discovered in South Africa can evade neutralization by most antibodies when expressed, but does not affect binding by convalescent plasma. This suggests the potential for reinfection with antigenically distinct variants and predicts reduced efficacy of spike-based vaccines.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Peter W. Horby et al.

Summary: Convalescent plasma therapy did not improve survival or other clinical outcomes in hospitalized COVID-19 patients.

LANCET (2021)

Add to Collection

Letter Medicine, General & Internal

WHO International Standard for anti-SARS-CoV-2 immunoglobulin

Paul A. Kristiansen et al.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Sandile Cele et al.

Summary: The study compared the neutralization of non-VOC and 501Y.V2 VOC variants using plasma from COVID-19 patients in South Africa. It found that plasma from individuals infected during the first wave effectively neutralized the first-wave virus variant, while plasma from those infected in the second wave effectively neutralized the 501Y.V2 variant.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Article Immunology

Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection

Jeremy Ratcliff et al.

Summary: The study reports diverse virological characteristics of UK intensive care patients with COVID-19, indicating higher viral loads in seronegative individuals and an increase in the frequency of the B.1.1.7 strain. These findings suggest different responses to treatment based on SARS-CoV-2 strain, viral loads, and antibody status.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Review Microbiology

SARS-CoV-2 variants, spike mutations and immune escape

William T. Harvey et al.

Summary: The evolution of SARS-CoV-2 has been characterized by the emergence of mutations and variants that impact virus characteristics. Manufacturers are preparing for possible updates to vaccines in response to changes in the virus population, and it is crucial to monitor genetic and antigenic changes alongside experiments to understand the impacts of mutations.

NATURE REVIEWS MICROBIOLOGY (2021)

Add to Collection

Review Immunology

Neutralizing monoclonal antibodies for treatment of COVID-19

Peter C. Taylor et al.

Summary: The study discusses the clinical utility of neutralizing monoclonal antibody therapies targeting SARS-CoV-2, emphasizing the importance of patient stratification, biomarkers, risk factors, and other clinical considerations.

NATURE REVIEWS IMMUNOLOGY (2021)

Add to Collection

Article Infectious Diseases

Serological assays for severe acute respiratory syndrome coronavirus 2 (BARS-CoV-2), March 2020

Ranawaka A. P. M. Perera et al.

EUROSURVEILLANCE (2020)

Add to Collection

Review Biotechnology & Applied Microbiology

The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection

Paul Kellam et al.

JOURNAL OF GENERAL VIROLOGY (2020)

Add to Collection

Article Hematology

Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19

Thomas Hueso et al.

BLOOD (2020)

Add to Collection

Article Multidisciplinary Sciences

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Thomas F. Rogers et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Ania Wajnberg et al.

SCIENCE (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.